Table 1.
First Author | Year | Study Design | Surgical Method | Number of Patients | Male/Female | Mean Age | Adjuvant Therapy | |||
---|---|---|---|---|---|---|---|---|---|---|
ERBT | ERBT | CTURBT | ERBT | CTURBT | ERBT | CTURBT | ||||
Zhu et al. [9] | 2008 | Retrospective | Holmium laser | 101 | 111 | 79/22 | 92/19 | N/A | N/A | Mitomycin |
Song1 et al. [10] | 2010 | Retrospective | Holmium laser | 64 | 51 | 52/12 | 40/11 | 72.50 | 74.50 | Mitomycin |
Song2 et al. [10] | 2010 | Retrospective | Holmium laser | 64 | 58 | 52/12 | 47/11 | 72.50 | 73.00 | Mitomycin |
Zhong1 et al. [11] | 2010 | Retrospective | Thulium laser | 30 | 42 | N/A | N/A | 68.30 | 66.26 | Epirubicin |
Zhong2 et al. [11] | 2010 | Retrospective | Holmium laser | 25 | 42 | N/A | N/A | 65.76 | 66.26 | Epirubicin |
Upadhyay [12] | 2012 | Prospective | Monopolar | 21 | 25 | N/A | N/A | N/A | N/A | N/A |
Liu et al. [13] | 2013 | RCT | Thulium laser | 64 | 56 | 46/18 | 40/16 | 67.10 | 66.30 | Epirubicin |
Tao et al. [14] | 2013 | Retrospective | KTP laser | 74 | 84 | 60/14 | 66/18 | 66.4 | 65.3 | Epirubicin |
Sureka [15] | 2014 | Prospective | Monopolar | 21 | 24 | N/A | N/A | 52.6 | 55 | BCG |
Yang et al. [16] | 2014 | Retrospective | KTP laser | 28 | 32 | 22/6 | 25/7 | 45.3 | 42.5 | Epirubicin |
Chen et al. [17] | 2015 | RCT | Thulium laser | 71 | 71 | 54/17 | 51/20 | 63 | 62 | Epirubicin |
Xu et al. [18] | 2015 | RCT | KTP laser | 99 | 94 | 80/19 | 76/18 | 63.06 | 62.82 | Pirarubicin |
Zhang et al. [19] | 2015 | RCT | Thulium laser | 149 | 143 | 70/79 | 79/64 | N/A | N/A | Epirubicin |
Chen et al. [20] | 2016 | Prospective | KTP laser | 83 | 75 | 60/23 | 51/24 | 63.43 | 65.31 | Mitomycin |
D’souza [21] | 2016 | Prospective | Holmium laser | 23 | 27 | 15/8 | 18/9 | 66.3 | 67.1 | Mitomycin |
Huang1 [22] | 2016 | Retrospective | Thulium laser | 70 | 70 | 50/20 | 48/22 | 58.31 | 57.87 | Epirubicin |
Huang2 et al. [22] | 2016 | Retrospective | Holmium laser | 70 | 70 | 45/25 | 48/22 | 59.97 | 57.87 | Epirubicin |
Cheng et al. [23] | 2017 | Retrospective | KTP laser | 34 | 30 | 28/6 | 27/3 | 59.41 | 63.13 | Mitomycin |
Zhang et al. [24] | 2017 | Retrospective | Monopolar | 40 | 50 | 35/5 | 38/12 | 60.65 | 60.8 | Pirarubicin |
Xu et al. [25] | 2018 | Retrospective | Thulium laser | 26 | 44 | 24/2 | 35/9 | 55.9 | 59.7 | Pirarubicin |
Bălan et al. [26] | 2018 | Prospective | Bipolar | 45 | 45 | N/A | N/A | 64.7 | 66.1 | BCG + Epirubicin |
Cheng et al. [27] | 2018 | Retrospective | Hybrid knife | 95 | 98 | 67/28 | 70/28 | 62.4 | 64.4 | Pirarubicin |
Li et al. [28] | 2018 | Retrospective | Thulium laser | 136 | 120 | 110/26 | 98/22 | N/A | N/A | Pirarubicin |
Liang et al. [29] | 2019 | Retrospective | KTP laser | 88 | 70 | 78/10 | 51/19 | N/A | N/A | Pirarubicin |
Bangash [30] | 2020 | Prospective | Monopolar | 41 | 41 | 34/7 | 36/5 | 58.46 | 58.59 | Mitomycin |
Gakis et al. [31] | 2020 | RCT | Hybrid knife | 56 | 59 | 45/11 | 47/12 | 66.8 | 70.2 | N/A |
Hashem [32] | 2020 | RCT | Holmium laser | 50 | 50 | 37/13 | 39/11 | 60.4 | 61.1 | Epirubicin |
Vladanov [33] | 2020 | Retrospective | Monopolar | 67 | 85 | 57/10 | 66/19 | 58.43 | 61.5 | Mitomycin |
Yang et al. [34] | 2020 | Prospective | Monopolar | 96 | 87 | 70/26 | 62/25 | 54.63 | 55.43 | Pirarubicin |
Poletajew et al. [35] | 2021 | Prospective | Monopolar | 153 | 274 | 117/36 | 201/63 | 68 | 69.5 | N/A |
Tripathi et al. [36] | 2021 | Prospective | KTP laser | 40 | 43 | 32/8 | 30/13 | 55.62 | 56.12 | Mitomycin |